RSS-Feed abonnieren

DOI: 10.1055/s-0044-1801369
Management of Cerebral Vasospasm after Aneurysmal Subarachnoid Hemorrhage: An Update
Autor*innen
Abstract
Cerebral vasospasm is one of the major complications of aneurysmal subarachnoid hemorrhage (aSAH). The term vasospasm generally refers to angiographical findings, and clinically is defined by delayed neurological deterioration and delayed cerebral ischemia. Symptomatic vasospasm occurs in 20 to 40% of aSAH patients and is one of the least understood components of management. Diagnosis can be made clinically by using bedside modalities and radiography. Management begins with the use of preventive modalities, augmentation of cerebral perfusion, attempts at reversal, and the use of brain protection. Early use of endovascular therapy with mechanical or pharmacological angioplasty remains a reasonable approach. Of proven benefit are the use of cerebral vasodilators such as nimodipine and milrinone and the use of induced hypertension for cerebral perfusion augmentation. Agents for the spasmogenic blockade, inhibition of smooth muscle contraction, and brain protection remain largely experimental. This narrative review aims to update readers on the mechanism, diagnosis, prevention, and management of vasospasm in aSAH.
Publikationsverlauf
Artikel online veröffentlicht:
05. März 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Etminan N, Chang HS, Hackenberg K. et al. Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis. JAMA Neurol 2019; 76 (05) 588-597
- 2 Kowalski RG, Claassen J, Kreiter KT. et al. Initial misdiagnosis and outcome after subarachnoid hemorrhage. JAMA 2004; 291 (07) 866-869
- 3 Gallas S, Tuilier T, Ebrahiminia V, Bartolucci P, Hodel J, Gaston A. Intracranial aneurysms in sickle cell disease: aneurysms characteristics and modalities of endovascular approach to treat these patients. J Neuroradiol 2020; 47 (03) 221-226
- 4 Ferguson S, Macdonald RL. Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2007; 60 (04) 658-667 , discussion 667
- 5 Alaraj A, Charbel FT, Amin-Hanjani S. Peri-operative measures for treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage. Neurol Res 2009; 31 (06) 651-659
- 6 Macdonald RL. Origins of the concept of vasospasm. Stroke 2016; 47 (01) e11-e15
- 7 Oka F, Chung DY, Suzuki M, Ayata C. Delayed cerebral ischemia after subarachnoid hemorrhage: experimental-clinical disconnect and the unmet need. Neurocrit Care 2020; 32 (01) 238-251
- 8 Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol 2014; 10 (01) 44-58
- 9 Kassell NF, Torner JC, Haley Jr EC, Jane JA, Adams HP, Kongable GL. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: overall management results. J Neurosurg 1990; 73 (01) 18-36
- 10 Kamezaki T, Yanaka K, Nagase S, Fujita K, Kato N, Nose T. Increased levels of lipid peroxides as predictive of symptomatic vasospasm and poor outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg 2002; 97 (06) 1302-1305
- 11 Ohta T, Satoh G, Kuroiwa T. The permeability change of major cerebral arteries in experimental vasospasm. Neurosurgery 1992; 30 (03) 331-335 , discussion 335–336
- 12 Iuliano BA, Pluta RM, Jung C, Oldfield EH. Endothelial dysfunction in a primate model of cerebral vasospasm. J Neurosurg 2004; 100 (02) 287-294
- 13 Foley PL, Takenaka K, Kassell NF, Lee KS. Cytotoxic effects of bloody cerebrospinal fluid on cerebral endothelial cells in culture. J Neurosurg 1994; 81 (01) 87-92
- 14 Mascia L, Fedorko L, Stewart DJ. et al. Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Stroke 2001; 32 (05) 1185-1190
- 15 Seifert V, Löffler BM, Zimmermann M, Roux S, Stolke D. Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg 1995; 82 (01) 55-62
- 16 Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg 2000; 92 (03) 390-400
- 17 Dumont AS, Dumont RJ, Chow MM. et al. Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery 2003; 53 (01) 123-133 , discussion 133–135
- 18 Flynn L, Andrews P. Advances in the understanding of delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage. F1000 Res 2015; 4: F1000 Faculty Rev-1200
- 19 Geraghty JR, Davis JL, Testai FD. Neuroinflammation and microvascular dysfunction after experimental subarachnoid hemorrhage: emerging components of early brain injury related to outcome. Neurocrit Care 2019; 31 (02) 373-389
- 20 Dreier JP, Major S, Manning A. et al; COSBID study group. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain 2009; 132 (Pt 7): 1866-1881
- 21 Charles AC, Baca SM. Cortical spreading depression and migraine. Nat Rev Neurol 2013; 9 (11) 637-644
- 22 Woitzik J, Dreier JP, Hecht N. et al; COSBID study group. Delayed cerebral ischemia and spreading depolarization in absence of angiographic vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2012; 32 (02) 203-212
- 23 Yundt KD, Grubb Jr RL, Diringer MN, Powers WJ. Autoregulatory vasodilation of parenchymal vessels is impaired during cerebral vasospasm. J Cereb Blood Flow Metab 1998; 18 (04) 419-424
- 24 Stein SC, Browne KD, Chen XH, Smith DH, Graham DI. Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study. Neurosurgery 2006; 59 (04) 781-787 , discussion 787–788
- 25 Budohoski KP, Czosnyka M, Kirkpatrick PJ, Smielewski P, Steiner LA, Pickard JD. Clinical relevance of cerebral autoregulation following subarachnoid haemorrhage. Nat Rev Neurol 2013; 9 (03) 152-163
- 26 Harrod CG, Bendok BR, Batjer HH. Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a review. Neurosurgery 2005; 56 (04) 633-654 , discussion 633–654
- 27 de Rooij NK, Greving JP, Rinkel GJE, Frijns CJM. Early prediction of delayed cerebral ischemia after subarachnoid hemorrhage: development and validation of a practical risk chart. Stroke 2013; 44 (05) 1288-1294
- 28 Pavelka M, Necarsulmer J, Ho J, Sasaki-Adams D. Vasospasm risk following aneurysmal subarachnoid hemorrhage in older adults. J Neurosurg 2023; 139 (05) 1302-1310
- 29 Afat S, Brockmann C, Nikoubashman O. et al. Diagnostic performance of different perfusion algorithms for the detection of angiographical spasm. J Neuroradiol 2018; 45 (05) 290-294
- 30 Fisher CM, Roberson GH, Ojemann RG. Cerebral vasospasm with ruptured saccular aneurysm–the clinical manifestations. Neurosurgery 1977; 1 (03) 245-248
- 31 Purkayastha S, Sorond F. Transcranial Doppler ultrasound: technique and application. Semin Neurol 2012; 32 (04) 411-420
- 32 Lam JM, Smielewski P, Czosnyka M, Pickard JD, Kirkpatrick PJ. Predicting delayed ischemic deficits after aneurysmal subarachnoid hemorrhage using a transient hyperemic response test of cerebral autoregulation. Neurosurgery 2000; 47 (04) 819-825 , 825–826
- 33 Lindegaard KF, Bakke SJ, Sorteberg W, Nakstad P, Nornes H. A non-invasive Doppler ultrasound method for the evaluation of patients with subarachnoid hemorrhage. Acta Radiol Suppl 1986; 369: 96-98
- 34 Sviri GE, Ghodke B, Britz GW. et al. Transcranial Doppler grading criteria for basilar artery vasospasm. Neurosurgery 2006; 59 (02) 360-366 , discussion 360–366
- 35 Hattingen E, Blasel S, Dumesnil R, Vatter H, Zanella FE, Weidauer S. MR angiography in patients with subarachnoid hemorrhage: adequate to evaluate vasospasm-induced vascular narrowing?. Neurosurg Rev 2010; 33 (04) 431-439
- 36 Washington CW, Zipfel GJ. Participants in the International Multi-disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Detection and monitoring of vasospasm and delayed cerebral ischemia: a review and assessment of the literature. Neurocrit Care 2011; 15 (02) 312-317
- 37 Claassen J, Mayer SA, Hirsch LJ. Continuous EEG monitoring in patients with subarachnoid hemorrhage. J Clin Neurophysiol 2005; 22 (02) 92-98
- 38 Rosenthal ES, Biswal S, Zafar SF. et al. Continuous electroencephalography predicts delayed cerebral ischemia after subarachnoid hemorrhage: a prospective study of diagnostic accuracy. Ann Neurol 2018; 83 (05) 958-969
- 39 Rass V, Solari D, Ianosi B. et al. Protocolized brain oxygen optimization in subarachnoid hemorrhage. Neurocrit Care 2019; 31 (02) 263-272
- 40 Ramakrishna R, Stiefel M, Udoteuk J. et al. Brain oxygen tension and outcome in patients with aneurysmal subarachnoid hemorrhage. J Neurosug 2008; 109 (06) 1075-1082
- 41 Gouvea Bogossian E, Diaferia D, Ndieugnou Djangang N. et al. Brain tissue oxygenation guided therapy and outcome in non-traumatic subarachnoid hemorrhage. Sci Rep 2021; 11 (01) 16235
- 42 Winberg J, Holm I, Cederberg D, Rundgren M, Kronvall E, Marklund N. Cerebral microdialysis-based interventions targeting delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage. Neurocrit Care 2022; 37 (01) 255-266
- 43 Veldeman M, Albanna W, Weiss M. et al. Invasive multimodal neuromonitoring in aneurysmal subarachnoid hemorrhage: a systematic review. Stroke 2021; 52 (11) 3624-3632
- 44 Greenberg ED, Gold R, Reichman M. et al. Diagnostic accuracy of CT angiography and CT perfusion for cerebral vasospasm: a meta-analysis. AJNR Am J Neuroradiol 2010; 31 (10) 1853-1860
- 45 Dankbaar JW, de Rooij NK, Rijsdijk M. et al. Diagnostic threshold values of cerebral perfusion measured with computed tomography for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke 2010; 41 (09) 1927-1932
- 46 Hong CM, Tosun C, Kurland DB, Gerzanich V, Schreibman D, Simard JM. Biomarkers as outcome predictors in subarachnoid hemorrhage–a systematic review. Biomarkers 2014; 19 (02) 95-108
- 47 Batista S, Bocanegra-Becerra JE, Claassen B. et al. Biomarkers in aneurysmal subarachnoid hemorrhage: a short review. World Neurosurg X 2023; 19: 100205
- 48 Polin RS, Bavbek M, Shaffrey ME. et al. Detection of soluble E-selectin, ICAM-1, VCAM-1, and L-selectin in the cerebrospinal fluid of patients after subarachnoid hemorrhage. J Neurosurg 1998; 89 (04) 559-567
- 49 Vajkoczy P, Meyer B, Weidauer S. et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005; 103 (01) 9-17
- 50 Macdonald RL, Kassell NF, Mayer S. et al; CONSCIOUS-1 Investigators. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008; 39 (11) 3015-3021
- 51 Amin-Hanjani S, Ogilvy CS, Barker II FG. Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis. Neurosurgery 2004; 54 (02) 326-334 , discussion 334–335
- 52 Lind ANR, Krabbenhøft MG, Valentin JB. et al. Cisternal and intraventricular irrigation in subarachnoid and intraventricular haemorrhage. Stroke Vasc Neurol 2024; (e-pub ahead of print).
- 53 Wolf S, Mielke D, Barner C. et al; EARLYDRAIN Study Group. Effectiveness of lumbar cerebrospinal fluid drain among patients with aneurysmal subarachnoid hemorrhage: a randomized clinical trial. JAMA Neurol 2023; 80 (08) 833-842
- 54 Hoh BL, Ko NU, Amin-Hanjani S. et al. 2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke 2023; 54 (07) e314-e370
- 55 Lannes M, Teitelbaum J, del Pilar Cortés M, Cardoso M, Angle M. Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol. Neurocrit Care 2012; 16 (03) 354-362
- 56 Zhao J, Zhou D, Guo J. et al; Fasudil Aneurysmal Subarachnoid Hemorrhage Study Group. Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. Neurol Med Chir (Tokyo) 2011; 51 (10) 679-683
- 57 Dorhout Mees SM, Algra A, Vandertop WP. et al; MASH-2 Study Group. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet 2012; 380 (9836) 44-49
- 58 Lee KH, Lukovits T, Friedman JA. “Triple-H” therapy for cerebral vasospasm following subarachnoid hemorrhage. Neurocrit Care 2006; 4 (01) 68-76
- 59 Schacht H, Küchler J, Boppel T. et al. Transluminal balloon angioplasty for cerebral vasospasm after spontaneous subarachnoid hemorrhage: a single-center experience. Clin Neurol Neurosurg 2020; 188: 105590
- 60 Molyneux A, Kerr R, Stratton I. et al; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet 2002; 360 (9342) 1267-1274
- 61 McDougall CG, Spetzler RF, Zabramski JM. et al. The barrow ruptured aneurysm trial. J Neurosurg 2012; 116 (01) 135-144
- 62 Darsaut TE, Roy D, Weill A. et al. A randomized trial of endovascular versus surgical management of ruptured intracranial aneurysms: interim results from ISAT2. Neurochirurgie 2019; 65 (06) 370-376
- 63 Raabe A, Beck J, Keller M, Vatter H, Zimmermann M, Seifert V. Relative importance of hypertension compared with hypervolemia for increasing cerebral oxygenation in patients with cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 2005; 103 (06) 974-981
- 64 Minhas JS, Moullaali TJ, Rinkel GJE, Anderson CS. Blood pressure management after intracerebral and subarachnoid hemorrhage: the knowns and known unknowns. Stroke 2022; 53 (04) 1065-1073
- 65 Gathier CS, van den Bergh WM, van der Jagt M. et al; HIMALAIA Study Group. Induced hypertension for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a randomized clinical trial. Stroke 2018; 49 (01) 76-83
- 66 Anetsberger A, Gempt J, Blobner M. et al. Impact of goal-directed therapy on delayed ischemia after aneurysmal subarachnoid hemorrhage: randomized controlled trial. Stroke 2020; 51 (08) 2287-2296
- 67 Springborg JB, Møller C, Gideon P, Jørgensen OS, Juhler M, Olsen NV. Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien) 2007; 149 (11) 1089-1101 , discussion 1101
- 68 Zhang J, Li H, Xu Z. et al. Oestrogen ameliorates blood-brain barrier damage after experimental subarachnoid haemorrhage via the SHH pathway in male rats. Stroke Vasc Neurol 2023; 8 (03) 217-228
- 69 Fung C, Z'Graggen WJ, Jakob SM. et al. Inhaled nitric oxide treatment for aneurysmal SAH patients with delayed cerebral ischemia. Front Neurol 2022; 13: 817072
- 70 Siuta M, Zuckerman SL, Mocco J. Nitric oxide in cerebral vasospasm: theories, measurement, and treatment. Neurol Res Int 2013; 2013: 972417
- 71 Suzuki H, Fujimoto M, Kawakita F. et al. Tenascin-C in brain injuries and edema after subarachnoid hemorrhage: Findings from basic and clinical studies. J Neurosci Res 2020; 98 (01) 42-56
- 72 Pickard JD, Murray GD, Illingworth R. et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989; 298 (6674) 636-642
- 73 Haley Jr EC, Kassell NF, Apperson-Hansen C, Maile MH, Alves WM. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg 1997; 86 (03) 467-474
- 74 Wong GKC, Poon WS, Chan MTV. et al; IMASH Investigators. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke 2010; 41 (05) 921-926
- 75 Macdonald RL, Higashida RT, Keller E. et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011; 10 (07) 618-625
- 76 Macdonald RL, Higashida RT, Keller E. et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke 2012; 43 (06) 1463-1469
- 77 Kirkpatrick PJ, Turner CL, Smith C, Hutchinson PJ, Murray GD, Collaborators STASH. STASH Collaborators. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. Lancet Neurol 2014; 13 (07) 666-675
- 78 Carlson AP, Hänggi D, Wong GK. et al; NEWTON Investigators. Single-dose intraventricular nimodipine microparticles versus oral nimodipine for aneurysmal subarachnoid hemorrhage. Stroke 2020; 51 (04) 1142-1149
- 79 Al-Tamimi YZ, Bhargava D, Feltbower RG. et al. Lumbar drainage of cerebrospinal fluid after aneurysmal subarachnoid hemorrhage: a prospective, randomized, controlled trial (LUMAS). Stroke 2012; 43 (03) 677-682
- 80 Lakhal K, Hivert A, Alexandre PL. et al. Intravenous milrinone for cerebral vasospasm in subarachnoid hemorrhage: the MILRISPASM controlled before-after study. Neurocrit Care 2021; 35 (03) 669-679
- 81 Gouvêa Bogossian E, Diaferia D, Minini A. et al. Time course of outcome in poor grade subarachnoid hemorrhage patients: a longitudinal retrospective study. BMC Neurol 2021; 21 (01) 196
- 82 Taufique Z, May T, Meyers E. et al. Predictors of poor quality of life 1 year after subarachnoid hemorrhage. Neurosurgery 2016; 78 (02) 256-264

